Jillian Richmond to Humans
This is a "connection" page, showing publications Jillian Richmond has written about Humans.
Connection Strength
0.467
-
Abdi W, Romasco A, Alkurdi D, Santacruz E, Okinedo I, Zhang Y, Kannan S, Shakiba S, Richmond JM. An overview of S100 proteins and their functions in skin homeostasis, interface dermatitis conditions and other skin pathologies. Exp Dermatol. 2024 Aug; 33(8):e15158.
Score: 0.036
-
Richmond JM, Patel D, Watanabe T, Chen HW, Martyanov V, Werner G, Garg M, Haddadi NS, Refat MA, Mahmoud BH, Wong LD, Dresser K, Deng A, Zhu JL, McAlpine W, Hosler GA, Feghali-Bostwick CA, Whitfield ML, Harris JE, Torok KS, Jacobe HT. CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in Fibroblasts. J Invest Dermatol. 2023 07; 143(7):1138-1146.e12.
Score: 0.032
-
Ryan GE, Harris JE, Richmond JM. Resident Memory T Cells in Autoimmune Skin Diseases. Front Immunol. 2021; 12:652191.
Score: 0.029
-
Egbeto IA, Garelli CJ, Piedra-Mora C, Wong NB, David CN, Robinson NA, Richmond JM. Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders. Front Immunol. 2020; 11:590558.
Score: 0.028
-
Groover MK, Richmond JM. Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases. F1000Res. 2020; 9:1197.
Score: 0.028
-
Garelli CJ, Refat MA, Nanaware PP, Ramirez-Ortiz ZG, Rashighi M, Richmond JM. Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis. Front Immunol. 2020; 11:1353.
Score: 0.027
-
Richmond JM, Strassner JP, Essien KI, Harris JE. T-cell positioning by chemokines in autoimmune skin diseases. Immunol Rev. 2019 05; 289(1):186-204.
Score: 0.025
-
Richmond JM, Strassner JP, Rashighi M, Agarwal P, Garg M, Essien KI, Pell LS, Harris JE. Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. J Invest Dermatol. 2019 04; 139(4):769-778.
Score: 0.024
-
Richmond JM, Strassner JP, Zapata L, Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, Harris JE. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018 07 18; 10(450).
Score: 0.024
-
Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. J Invest Dermatol. 2017 02; 137(2):350-358.
Score: 0.021
-
Richmond JM, Harris JE. Immunology and skin in health and disease. Cold Spring Harb Perspect Med. 2014 Dec 01; 4(12):a015339.
Score: 0.018
-
Richmond J, Tuzova M, Cruikshank W, Center D. Regulation of cellular processes by interleukin-16 in homeostasis and cancer. J Cell Physiol. 2014 Feb; 229(2):139-47.
Score: 0.017
-
Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013 Dec; 25(6):676-82.
Score: 0.017
-
Richmond JM, Lee J, Green DS, Kornfeld H, Cruikshank WW. Mannose-capped lipoarabinomannan from Mycobacterium tuberculosis preferentially inhibits sphingosine-1-phosphate-induced migration of Th1 cells. J Immunol. 2012 Dec 15; 189(12):5886-95.
Score: 0.016
-
Richmond JM, Duffy ER, Lee J, Kaboli K, Kim YS, Remick DG, Kornfeld H, Cruikshank WW. Mannose-capped Lipoarabinomannan from Mycobacterium tuberculosis induces soluble tumor necrosis factor receptor production through tumor necrosis factor alpha-converting enzyme activation. Infect Immun. 2012 Nov; 80(11):3858-68.
Score: 0.016
-
Richmond J, Finkel M, Studwell A, Little F, Cruikshank W. Introduction of pro-interleukin-16 inhibits T-lymphoblastic leukemia growth in mice. J Cancer Res Clin Oncol. 2011 Oct; 137(10):1581-5.
Score: 0.015
-
Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, Morrison L, Chaney K, Kupper TS, Curiel-Lewandrowski C, Cruikshank W. Interleukin-16 as a marker of S?zary syndrome onset and stage. J Clin Immunol. 2011 Feb; 31(1):39-50.
Score: 0.014
-
Rabin A, Bello E, Kumar S, Zeki DA, Afshari K, Deshpande M, Francis N, Khalighinejad F, Umeton R, Radu I, Qutab F, Kwong D, Kurban M, Hemond C, Richmond JM, Ionete C. Targeted proteomics of cerebrospinal fluid in treatment na?ve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes. Sci Rep. 2024 09 18; 14(1):21793.
Score: 0.009
-
Tang Q, Fakih HH, Zain Ui Abideen M, Hildebrand SR, Afshari K, Gross KY, Sousa J, Maebius AS, Bartholdy C, S?gaard PP, Jackerott M, Hariharan V, Summers A, Fan X, Okamura K, Monopoli KR, Cooper DA, Echeverria D, Bramato B, McHugh N, Furgal RC, Dresser K, Winter SJ, Biscans A, Chuprin J, Haddadi NS, Sherman S, Yildiz-Altay ?, Rashighi M, Richmond JM, Bouix-Peter C, Blanchard C, Clauss A, Alterman JF, Khvorova A, Harris JE. Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nat Commun. 2023 11 04; 14(1):7099.
Score: 0.009
-
Dittrich K, Yildiz-Altay ?, Qutab F, Kwong DA, Rao Z, Nievez-Lozano SA, Gardner HL, Richmond JM, London CA. Baseline tumor gene expression signatures correlate with chemoimmunotherapy treatment responsiveness in canine B cell lymphoma. PLoS One. 2023; 18(8):e0290428.
Score: 0.008
-
Refat MA, Strassner JP, Frisoli ML, Rashighi M, Richmond J, Nada E, Saleh R, El-Hamd MA, Goldberg D, Mahmoud BH, Harris JE. Lesional CD8+ T-Cell Number Predicts Surgical Outcomes of Melanocyte-Keratinocyte Transplantation Surgery for Vitiligo. J Invest Dermatol. 2023 11; 143(11):2275-2282.e6.
Score: 0.008
-
Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol. 2022 03; 18(3):263-272.
Score: 0.008
-
Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immun Inflamm Dis. 2021 12; 9(4):1101-1145.
Score: 0.007
-
Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. J Invest Dermatol. 2020 07; 140(7):1446-1449.e4.
Score: 0.007
-
Riding RL, Richmond JM, Harris JE. Mouse Model for Human Vitiligo. Curr Protoc Immunol. 2019 02; 124(1):e63.
Score: 0.006
-
Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017 May; 76(5):847-855.e5.
Score: 0.005
-
Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017 Jan; 76(1):150-151.e3.
Score: 0.005
-
Tuzova M, Richmond J, Wolpowitz D, Curiel-Lewandrowski C, Chaney K, Kupper T, Cruikshank W. CCR4+T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16. Leuk Lymphoma. 2015 Feb; 56(2):440-9.
Score: 0.004
-
Curiel-Lewandrowski C, Yamasaki H, Si CP, Jin X, Zhang Y, Richmond J, Tuzova M, Wilson K, Sullivan B, Jones D, Ryzhenko N, Little F, Kupper TS, Center DM, Cruikshank WW. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma. J Clin Invest. 2011 Dec; 121(12):4838-49.
Score: 0.004